In recent days, national attention has been drawn to a new policy implemented this spring by the current administration that has resulted in the forcible separation of children from immigrant families. No one needs the opinion of a doctoral-level psychologist to understand that such separations are devastatingly cruel to the families involved. What policy makers are less likely to understand are the pernicious and often life-long effects of adverse childhood experiences (ACEs). How will we as a profession respond?

A very happy birthday to Dr. Zoltan Gross who is turning 98 years old.

If you missed the live-session webinar, watch now! Dr. Zelechoski reviews the types of requests for information that practitioners may receive for various legal purposes, including subpoenas and court orders.

It is the nature of scientific inquiry to seek greater specificity in understanding natural phenomena, and our clinical research colleagues strive valiantly to do so. But the scientific method can lead us astray in that it demands a focus on problems, not patients. In this column, I analyze our lack of success in ameliorating the global burden of mental distress and suggest that crowdsourcing, a strategy enabled by widespread electronic communications, might provide a solution towards making effective interventions more widely available.

For the 2018-22 term, to further its mission and effectively address priorities, CDIP is seeking nominees with lived experience of disability culture, knowledge of the principles and implementation of Universal Design, commitment to disability inclusion within psychology and among various sectors of society, knowledge of human rights and law, and/or firsthand experience in APA governance, including at the state, regional, divisional or national level.

A recently published database tracking pharmaceutical company donations to not-for-profit associations provides data indicating that industry funding provides significant revenue to patient advocacy groups. Other data suggest that this funding might be intended to create informal lobbying groups that can act on behalf of drug manufacturers. While drug company promotional activities are not newsworthy, the absence of mental health associations from the list of funded groups raises questions about the influence of mental health advocacy.